Bantovet20 gm

Bantovet is a mid-potency topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Established / Approved Uses

• Eczema (including atopic, infantile, and discoid eczema)
• Psoriasis, excluding widespread plaque psoriasis
• Seborrhoeic dermatitis
• Neurodermatoses (lichen simplex, lichen planus)
• Contact/irritant dermatitis and contact sensitivity reactions
• Prurigo nodularis
• Discoid lupus erythematosus (localized skin lesions)

Bantovet should be used only for the corticosteroid-responsive skin condition diagnosed and prescribed by a physician; it is not intended for indiscriminate or self-directed use on undiagnosed skin lesions.

Each gram of cream or ointment contains Betamethasone Valerate BP equivalent to 0.1% w/w Betamethasone, in a suitable topical cream, ointment, or lotion base.

Bantovet is a mid-potency (Group 3, per the US 7-tier topical corticosteroid potency ranking) synthetic glucocorticoid formulated for topical use on the skin. It is available as a cream, ointment, or lotion, typically at a strength of 0.1%. Bantovet works by reducing inflammation, itching, and redness in a range of corticosteroid-responsive skin conditions. It is intended for dermatologic (skin) use only and is not for ophthalmic, oral, or long-term unsupervised use.

Bantovet belongs to the topical corticosteroid (glucocorticoid) class of dermatological preparations. It is classified as a mid-potency (intermediate-strength) topical steroid.

Betamethasone Valerate is a synthetic corticosteroid that diffuses across cell membranes and binds to intracellular glucocorticoid receptors in skin cells. This receptor-hormone complex translocates to the nucleus and modulates gene transcription, inducing synthesis of lipocortins (proteins that inhibit phospholipase A2), which in turn reduces the release of arachidonic acid and downstream inflammatory mediators such as prostaglandins and leukotrienes.

The overall effect of Betamethasone Valerate is anti-inflammatory, antipruritic (anti-itch), and vasoconstrictive action in the skin, which together relieve redness, swelling, and itching in corticosteroid-responsive dermatoses. Systemic absorption through intact skin is normally low but increases substantially with use on thin or broken skin, large body surface areas, occlusive dressings, and in infants and young children.

• Wash and dry hands before and after applying Bantovet, unless the hands are the area being treated.
• Apply a thin film of Bantovet only to the affected skin area; avoid unaffected skin.
• Gently rub in until the Bantovet cream, ointment, or lotion is absorbed.
• Do not cover the treated area with airtight (occlusive) dressings or plastic wrap unless a physician has specifically directed this.
• Avoid contact with the eyes, lips, and mucous membranes.
• Do not apply Bantovet to the face, groin, or armpits for prolonged periods unless directed by a physician.
• Do not use Bantovet on broken or infected skin unless an appropriate antimicrobial is also being used, as directed by a physician.

Bantovet is applied topically and systemic drug interactions are uncommon when it is used as directed on limited areas of intact skin. However, clinically relevant interactions can occur in specific situations:

• Other topical or systemic corticosteroids: Concurrent use with other corticosteroid-containing products increases the total corticosteroid exposure and the risk of HPA-axis suppression and systemic side effects; avoid combining without medical advice.
• Occlusive dressings or other topical agents that increase skin permeability: These substantially increase systemic absorption of Bantovet and the risk of systemic corticosteroid effects.
• CYP3A4 inhibitors (e.g., ritonavir, itraconazole): Theoretically, potent CYP3A4 inhibitors could increase systemic corticosteroid levels if significant absorption occurs (e.g., with extensive or prolonged use); clinical significance with limited topical use of Bantovet is low but caution is advised with widespread application.

Local skin reactions are the most common adverse effects of Bantovet and are usually related to the strength, duration, and area of application:

• Burning, stinging, itching, and dryness at the application site
• Skin thinning (atrophy), striae (stretch marks), and telangiectasia (visible small blood vessels)
• Folliculitis, hypertrichosis (increased hair growth), and acneiform eruptions
• Hypopigmentation or hyperpigmentation of the treated skin
• Perioral dermatitis and allergic contact dermatitis
• Maceration of the skin and secondary skin infection
• Miliaria (heat rash)

With extensive use, prolonged use, use under occlusion, or use on large areas or broken skin, systemic absorption of Bantovet can occur, which may rarely cause features of hypercorticism (Cushingoid features), HPA-axis suppression, hyperglycemia, and glucosuria — see Precautions and Warnings.

Pregnancy: There are no adequate, well-controlled studies of Bantovet in pregnant women. Topical corticosteroids have been shown to be teratogenic in animal studies when given in sufficient systemic quantities. Bantovet should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; avoid use over large areas, for prolonged periods, or under occlusion during pregnancy. Consult a physician before use.

Lactation: It is not known whether topical application of Bantovet results in sufficient systemic absorption to produce detectable amounts in human breast milk. Caution should be exercised when Bantovet is used by a breastfeeding woman; avoid applying it to the breast/nipple area before nursing, and consult a physician before use.

HPA-Axis Suppression

Systemic absorption of Bantovet can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria. This risk increases with the use of higher potency products, large treatment areas, prolonged use, use under occlusive dressings, and use in infants and young children (due to a larger skin-surface-to-body-weight ratio).

Occlusive Dressings

Occlusive dressings substantially increase percutaneous absorption of Bantovet and should only be used if specifically directed by a physician.

Special Sites

Avoid prolonged use of Bantovet on the face, groin, and axillae (armpits), which are more susceptible to atrophic skin changes. Bantovet is not for ophthalmic use — avoid contact with the eyes, as prolonged exposure may increase the risk of cataracts or glaucoma. Bantovet should not be used for rosacea, acne vulgaris, or perioral dermatitis, as it may worsen these conditions.

Skin Infections

If a skin infection is present or develops, an appropriate antimicrobial agent should be used; if a favorable response does not occur promptly, Bantovet should be discontinued until the infection is adequately controlled.

Local Irritation and Sensitization

Bantovet may cause contact sensitization or local irritation. If irritation develops or worsens, Bantovet should be discontinued and appropriate therapy instituted.

Duration of Use

Bantovet should not be used for prolonged, continuous periods (see Duration of Treatment). If no improvement is seen within 2 weeks, treatment should be reassessed by a physician.

Excessive or prolonged use of Bantovet over large areas, especially under occlusion or in children, can lead to sufficient systemic absorption to produce features of hypercorticism (Cushingoid features), HPA-axis suppression, hyperglycemia, and glucosuria. Accidental ingestion of Bantovet is unlikely to cause significant toxicity from a small topical preparation, but any suspected overdose, accidental ingestion, or signs of systemic corticosteroid effects (e.g., unusual weight gain, moon face, muscle weakness) should prompt immediate medical attention. Contact a physician, hospital emergency department, or a poison control center promptly; do not attempt to manage a suspected overdose at home without medical guidance.

Store Bantovet at room temperature (below 30°C), away from direct light and moisture. Do not freeze. Keep the container tightly closed when not in use, and keep out of the reach and sight of children.

Pediatric patients: See Pediatric Use.

Elderly patients: Elderly patients may have thinner, more fragile skin and may be more susceptible to skin atrophy, bruising, and local irritation with Bantovet; use the lowest effective amount for the shortest necessary duration.

Renal and hepatic impairment: Specific dose adjustment data for topical Bantovet in renal or hepatic impairment are not established, as systemic exposure from normal topical use is minimal; however, if extensive body surface areas are treated (increasing systemic absorption), caution and physician supervision are advised in patients with significant hepatic impairment, as corticosteroid metabolism may be reduced.

Pregnancy and lactation: See Pregnancy and Lactation.

Bantovet is intended for short-term, intermittent use. Continuous therapy is generally limited to a maximum of about 2–4 weeks, and many labels recommend reassessment if there is no improvement within 2 weeks. Once symptoms improve, the frequency of application of Bantovet should be reduced, and treatment should be discontinued as soon as clinically appropriate. Prolonged, continuous use — especially on the face, in skin folds, under occlusion, or in children — should be avoided due to the increased risk of skin atrophy and HPA-axis suppression; any need for longer-term use should be reviewed by a physician.

Topical Corticosteroids; Glucocorticoids; Dermatological Preparations

Betamethasone Valerate exerts its effect by binding to cytoplasmic glucocorticoid receptors within skin cells. The activated receptor complex moves into the cell nucleus and alters gene transcription, increasing production of anti-inflammatory proteins (such as lipocortin-1, which inhibits phospholipase A2) and decreasing production of pro-inflammatory mediators (such as prostaglandins, leukotrienes, and cytokines). This produces the characteristic anti-inflammatory, antipruritic, and vasoconstrictive effects of Betamethasone Valerate on the skin, reducing redness, swelling, and itching in corticosteroid-responsive dermatoses.

C (FDA legacy pregnancy category)

Bantovet is not recommended for use in infants under 1 year of age due to a higher risk of HPA-axis suppression and systemic absorption in this age group. Safety and efficacy of Bantovet in infants under 1 year have not been established.

In children 1 year of age and older, Bantovet may be used under medical supervision, but children are more susceptible than adults to HPA-axis suppression and Cushing's syndrome because of a larger skin-surface-to-body-weight ratio. Use in children should be limited to the least amount compatible with an effective treatment regimen, for the shortest possible duration, and occlusive dressings should generally be avoided. Long-term use of Bantovet in children has been associated with growth retardation, delayed weight gain, and (rarely) intracranial hypertension; growth and development should be monitored periodically in children requiring prolonged treatment.